Grupo BMH

Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis

  • Majority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1]
     
  • Scalp psoriasis affects 60 million people worldwide - a difficult-to-treat form of psoriasis with a substantial impact on quality of life[1]-[5]
     
  • Cosentyx data presented at AAD adds to robust evidence demonstrating sustained efficacy in plaque, nail, palmoplantar and scalp psoriasis as well as psoriatic arthritis[6]-[12]

The digital press ...

16 February 2018    Subscribirse

Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis

  • Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1]
     
  • Findings show absolute PASI <=1/<=2/<=3 responses were sustained in those treated with Cosentyx from Year 1 to Year 5[1]
     
  • Cosentyx is the first and only fully human interleukin-17A (IL-17A) inhibitor that showed sustained skin clearance rates at 5 years in patients from a psoriasis Phase III study[2]  

The digital ...

16 February 2018    Subscribirse

Novartis forms alliance to develop medicines for treating infectious diarrheal disease

  • Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis
     
  • Cryptosporidiosis is the second leading cause of infectious diarrhea in children
     
  • Private companies, governments, non-governmental organizations, academia, and other stakeholders need to work together to create sustainable solutions for global health issues.

Basel, February 14, 2018 -Novartis and the Bill & Melinda Gates Foundation ...

14 February 2018    Subscribirse

Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis

  • Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL
     
  • Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a complete range of dosing options
     
  • A full range of patient support services for Glatopa® is available through GlatopaCare®

Holzkirchen, February 13, 2018 - Sandoz, a Novartis division, today announced ...

13 February 2018    Subscribirse

Potential weight loss treatment takes shape with help from patients

James Zervios grew up in a time when schoolyard bullying was met with a shrug. Teased for his weight and picked last for sports teams, Zervios sought solace at the end of the day in the comforts of home. In his Italian and Greek household, comfort was often in the form of food. His family celebrated every life event with an Italian feast and gathered each Sunday for a four-course family dinner, so food was not only plentiful – it felt like a reaffirming embrace.

It wasn’t until later that Zervios realized that comfort came at the expense of his health. The pounds accumulated over the ...

12 February 2018    Subscribirse